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blasts (Kolar et al., 2010). Particularly MSCs are considered to 
play a pivotal role in an adequate healing process, since they are 
able to differentiate into both chondrocytes and osteoblasts/os-
teocytes, thereby facilitating bone healing (Knight and Hanken-
son, 2013). The transcription factor runt-related transcription 
factor (RUNX2) drives MSCs towards the osteogenic lineage, 
while its secreted downstream target phosphoprotein 1 (SPP1) 
is a key marker for early osteogenesis and is also induced by hy-
poxia-inducible factor 1 (HIF-1; HIF1A) (Gross et al., 2005; Li 
et al., 2004). Furthermore, matrix metalloproteinase 2 (MMP2) 
and MMP9, which are fundamental for appropriate bone healing 
(Henle et al., 2005), are induced via the HIF-1 pathway (Luo et 
al., 2006; O’Toole et al., 2008).
1  Introduction
The healing of approximately 10% of bone fractures is impaired, 
and this is accompanied by pain and suffering of the affected pa-
tients and tremendous socio-economic costs (Gomez-Barrena 
et al., 2015; Gaston and Simpson, 2007). During the process of 
fracturing, the bone marrow canal is opened and adjacent blood 
vessels rupture. The cells emerging from the bone marrow (e.g., 
mesenchymal stromal cells – MSCs, hematopoietic progeni-
tor cells and premature lymphocytes) mix with peripheral blood 
in the fracture gap, coagulate and form the fracture hematoma 
(FH). Local inflammation appears to promote the migration and 
recruitment of MSCs, endothelial cells, immune cells and fibro-
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Abstract
The aim of the study was to establish an in vitro fracture hematoma (FH) model that mimics the in vivo situation of the 
human fracture gap in order to assess drug efficacy and effectiveness for the treatment of fracture healing disorders. 
Human peripheral blood and mesenchymal stromal cells (MSCs) were coagulated to produce in vitro FH models, which 
were incubated in osteogenic medium under normoxia/hypoxia and analyzed for cell composition, gene expression 
and cytokine/chemokine secretion. To evaluate the model, we studied the impact of dexamethasone (impairing fracture 
healing) and deferoxamine (promoting fracture healing). Under hypoxic conditions, MSCs represented the predominant 
cell population, while the frequencies of leukocyte populations decreased. Marker gene expression of osteogenesis, 
angiogenesis, inflammation, migration and hypoxic adaptation increased significantly over time and compared to nor-
moxia, while cytokine/chemokine secretion remained unchanged. Dexamethasone favored the frequency of immune 
cells compared to MSCs, suppressed osteogenic and pro-angiogenic gene expression, and enhanced the secretion 
of inflammatory cytokines. Conversely, deferoxamine favored the frequency of MSCs over that of immune cells and 
enhanced the expression of the osteogenic marker RUNX2 and markers of hypoxic adaptation. In summary, we 
demonstrate that hypoxia is an important factor for modeling the initial phase of fracture healing in vitro and that both 
fracture-healing disrupting and promoting substances can influence the in vitro model comparable to the in vivo situation. 
Therefore, we conclude that our model is able to mimic in part the human FH and could reduce the number of animal 
experiments in early preclinical studies. 
This is an Open Access article distributed under the terms of the Creative Commons 
Attribution 4.0 International license (http://creativecommons.org/licenses/by/4.0/), 
which permits unrestricted use, distribution and reproduction in any medium, provi-
ded the original work is appropriately cited. 
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Until now, research concerning fracture healing is most often 
performed using animal, particularly rodent, models (mice and 
rats). Not only the size of the rodents differs from human patients 
(Perlman, 2016); also the similarity of the inflammatory pro-
cess in rodents and men is controversially discussed (Mestas and 
Hughes, 2004; Seok et al., 2013; Takao and Miyakawa, 2015). 
Apart from the advantages of using mice to study certain path-
ways and systemic effects (e.g., easy to handle, requirement of 
little space, gene editing possible), the difference in species-spe-
cific evolutionary pressure and the resulting molecular and ana-
tomical differences have to be considered carefully in evaluating 
the relevance of the rodent model. These differences include the 
lack of the Haversian system, a microtubule system that provides 
the space for blood vessels and nerves to grow (Bagi et al., 2011; 
Jowsey, 1966). 
We previously studied the cell composition, RNA and cytokine 
profile of FHs obtained from human patients (Hoff et al., 2013, 
2016; Kolar et al., 2010, 2011). Based on these findings, we here 
developed a human in vitro model of the FH in order (i) to mim-
ic the initial phase of fracture healing, (ii) to contextualize the ob-
tained data to existing ex vivo and in vivo data, and (iii) to use this 
system to analyze the impact of drugs/therapies relevant for frac-
ture healing in order to (iv) reduce animal numbers in research 
and accelerate translation in this area.
2  Materials and methods
Blood sampling, bone marrow-derived MSC isolation and  
cultivation
Blood was collected in 6 mL EDTA Vacutainers (Becton Dickin-
son, Franklin Lakes, USA) from healthy donors.
Human mesenchymal stromal cells (hMSCs) were isolat-
ed from bone marrow of patients undergoing total hip replace-
ment (provided by the Center for Musculoskeletal Surgery, 
Charité-Universitätsmedizin Berlin and distributed via the 
“Tissue Harvesting” core facility of the BCRT). All procedures 
were approved by the Charité-Universitätsmedizin Ethics Com-
mittee and were performed according to the Helsinki Declaration 
(ethical approval EA1/012/13). 
Bone marrow was transferred to a 175 cm2 cell tissue flask 
(Greiner Bio-one, Kremsmünster, Austria) and incubated in 
DMEM + GlutaMAX™ (Gibco, Carlsbad, USA) supplemented 
with 10% FCS (Biowest, Riverside, USA), 1% Penicillin/Strep-
tomycin (Gibco, Carlsbad, USA) and 20% StemMACS™ MSC 
Expansion Media Kit XF (Miltenyi Biotech, Bergisch Gladbach, 
Germany) in a humidified atmosphere (37°C, 5% CO2, 95% room 
air). After 2 days of cultivation, the supernatant was discarded, 
and the adherent cells were washed three times using PBS. From 
then on, the cell culture medium was changed once a week; cells 
with a confluence of 80-90% were passaged using Trypsin-EDTA. 
Bone marrow-derived non-differentiated hMSCs in passage 
3-4 were used for all FH models. 
In order to replace FCS during MSC propagation, we used 
xeno-free 20% StemMACS™ MSC Expansion Media Kit XF 
(Miltenyi Biotech, Bergisch Gladbach, Germany). When trying 
Additionally, MSCs can attract other cells that are crucial for 
the ongoing regeneration process such as T cells, granulocytes 
and macrophages towards the fracture site. In brief, MSCs in a 
pro-inflammatory microenvironment distinctly secrete chemo-
kine (C-X-C motif) ligand (CXCL)9, CXCL10, macrophage in-
flammatory protein (MIP)-1α, MIP-1β and Rantes, thereby en-
hancing lymphocyte recruitment. Additionally, granulocytes are 
recruited through the enhanced secretion of granulocyte-macro-
phage colony-stimulating factor (GM-CSF), interleukin 6 (IL-6) 
and IL-8 (Le Blanc and Davies, 2015). 
During the initial phase of fracture healing, i.e., within the first 
1-5 days after the fracture (Annamalai et al., 2018), immune cells 
play a pivotal role. Their inflammatory activity can be considered a 
double-edged sword for the bone healing process. Although useful 
in initiating the bone healing process by recruiting MSCs and endo-
thelial cells to the fracture site via cytokine signaling, immune cells 
also prolong the healing process by perpetuating the inflammato-
ry response (El-Jawhari et al., 2016). More in detail, granulocytes 
as well as monocytes/macrophages and natural killer (NK) cells 
are involved in the clearance of debris (Baht et al., 2018; Thomas 
and Puleo, 2011), NK-cells recruit MSCs towards the fracture site, 
while monocytes/macrophages conduct re-vascularization. T cells 
are assumed to orchestrate the inflammatory process during the ini-
tial phase of fracture healing by retaining but also attenuating the 
inflammation (El-Jawhari et al., 2016). However, the distinct roles 
of immune cell populations and their temporal and spatial distribu-
tion and composition within the FH still remain unclear.
Due to the disruption of the blood supply, the FH is charac-
terized by a severe lack of nutrients and oxygen (Hoff et al., 
2016). Cellular adaptation towards the hypoxic microenviron-
ment of the fracture gap is mainly driven by HIF-1, which reg-
ulates the switch from oxidative phosphorylation towards gly-
colysis and also promotes the reestablishment of vascularization 
(Cramer et al., 2003). HIF-1 induces genes of the glycolytic cas-
cade such as phosphoglycerate kinase (PGK1) and lactate dehy-
drogenase (LDHA), and genes encoding pro-angiogenic factors 
such as vascular endothelial growth factor (VEGFA) and IL-8 
(Liu et al., 2012; Dengler et al., 2014). The inflammatory milieu 
in the FH is inter alia characterized by the presence of pro-in-
flammatory cytokines, e.g., IL-6 and IL-8, which are abundantly 
secreted during the initial phase leading to cell activation, and the 
recruitment of further immune cells into the fracture site via, e.g., 
CXC-motif chemokine receptor 4 (CXCR4) (Liu et al., 2012). 
Especially the initial phase of fracture healing within the FH is 
susceptible to fracture healing disorders, which can lead to de-
layed or even incomplete healing of the affected bone (Claes et 
al., 2012; Schindeler et al., 2008). 
The experimental removal of the FH in a rat femoral fracture 
model prolonged the healing process (Grundnes and Reikeras, 
1993), while the implantation of a FH improved bone healing 
(Mizuno et al., 1990; Tachibana et al., 1991). Specifically, Mizu-
no et al. (1990) transplanted the hematoma of the rat’s femur to 
subperiosteal sites, observing new bone formation there, indicat-
ing strong osteogenic potential. Tachibana et al. (1991) used fluid 
material of human FHs, which induced osteoblast proliferation in 
the osteoblast-like cell line MC3T3E1.
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to fully replace FCS by using pooled human platelet lysate ac-
cording to the protocol of Schallmoser and Strunk (2009), we ob-
served detachment of MSCs from the plastic surface of incuba-
tion chambers and additionally the absence of the typical charac-
terization marker CD90 as determined by flow cytometry. Thus, 
we had to postpone the replacement of FCS, which will be in the 
focus of future studies. 
Differentiation and characterization of bone  
marrow-derived MSCs
Bone marrow-derived MSCs were plated at a density of 1x104 
cells per well in 96-well plates (Greiner Bio-one, Kremsmünster, 
Austria) and subsequently cultivated in the respective differentia-
tion media, i.e., StemMACS™ AdipoDiff for adipogenic or Stem-
MACS™ OsteoDiff (both Miltenyi Biotech, Bergisch Gladbach, 
Germany) for osteogenic differentiation, respectively, with week-
ly medium changes. After 3 weeks, samples of MSCs were fixed 
in 4% paraformaldehyde for 10 min at room temperature (RT). For 
evaluation of adipogenic differentiation, fixed MSCs were stained 
with a freshly prepared 60% Red Oil O (Sigma-Aldrich Chemie 
Gmbh, Munich, Germany) working solution solved in ddH2O 
(stock solution: 0.3% Red Oil O solved in 100% isopropanol) for 
15 min at RT and washed with 60% isopropanol. Lipid droplets 
were analyzed via microscopy. For evaluation of osteogenic dif-
ferentiation, fixed MSCs were stained with 0.5% Alizarin Red 
(Sigma Aldrich, St. Louis, USA) dissolved in H2Odd for 15 min 
at RT to visualize calcium deposition via microscopy (Fig. S11).
Immunophenotyping of bone marrow-derived MSCs via the 
expression profile of typical surface markers (CD73+, CD90+, 
CD105+; CD34-, CD45-, CD20-, CD14-, HLA-DR-) was con-
ducted using the MSC Phenotyping Kit (Miltenyi Biotech, Ber-
gisch Gladbach, Germany) according to the manufacturer’s in-
structions (Fig. S21).
Only cell cultures that fulfilled the minimal criteria for MSCs 
set by the Mesenchymal and Tissue Stem Cell Committee of 
the International Society for Cellular Therapy (Dominici et al., 
2006), including differentiation towards adipogenic and osteo-
genic lineage and expression of the respective surface marker 
profile (Fig. S1 and S21), were used for the experiments.
Generation of 3D in vitro FH models
To generate the in vitro FH models, we firstly isolated, expand-
ed and characterized MSCs before using them in subsequent al-
logenic combination with human whole blood, which was pro-
cessed immediately. To this end, 2.5 x 105 per well MSCs with-
out any pre-differentiation were centrifuged at 300 g for 3 min 
at 4°C in a 96-well plate (U-bottom, Greiner Bio one, Krems-
münster, Austria). After discarding the supernatant, the cell 
pellet was resuspended in 100 µL CaCl2 (10 mM in PBS). 
100 µL of allogenic EDTA-blood was added and gently mixed 
by pipetting. After 30 min of incubation at 37°C, 5% CO2, the 
coagulated in vitro FH models were transferred into DMEM + 
GlutaMAX™ supplemented with 10% FCS, 100 units/mL pen-
icillin, 100 mg/mL streptomycin, 0.2% β-glycerophosphate 
(Sigma Aldrich, St. Louis, USA), 10-8 M dexamethasone (Sig-
ma Aldrich, St. Louis, USA) and 0.002% ascorbic acid (Sigma 
Aldrich, St. Louis, USA), within this study further referred to  as 
osteogenic medium (OM). 
For the treatment studies, either 10-7 dexamethasone (DEX, im-
pairing fracture healing) or 250 µmol deferoxamine (DFO, pro-
moting fracture healing) was added to the medium. Then, the gen-
erated in vitro FHs were incubated under either hypoxia (37°C, 
5% CO2 and 1% O2) or normoxia (37°C, 5% CO2 and 18% O2) 
in a humidified atmosphere for up to 48 h. Hypoxic conditions 
were achieved using an incubator (Binder, Tuttlingen, Germany) 
flushed with nitrogen. Normoxic and hypoxic conditions were 
1 doi:10.14573/altex.1910211s
Tab. 1: Blood donors and MSC donors for the generation of the in vitro fracture hematomas
Donor Cell type  Age Sex FH model Impact of hypoxiaa Impact of DFO/DEXa
B1 blood 44 m MSC1, MSC2 FC, GE, CCS -
B2 blood 23 m MSC1, MSC2 FC, GE, CCS -
B3 blood 27 m MSC1, MSC2 FC, GE, CCS -
MSC1 bmMSCs 77 m B1, B2, B3 FC, GE, CCS -
MSC2 bmMSCs 75 m B1, B2, B3 FC, GE, CCS -
B4 blood 37 m MSC3, MSC4 - FC, GE, CCS
B5 blood 26 m MSC3, MSC4 - FC, GE, CCS
B6 blood 38 m MSC3, MSC4 - FC, GE, CCS
MSC3 bmMSCs 72 m B4, B5, B6 - FC, GE, CCS
MSC4 bmMSCs 62 m B4, B5, B6 - FC, GE, CCS
a FC, flow cytometry analysis; GE, gene expression analysis; CCS, cytokine/chemokine secretion analysis
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Kit (QIAGEN GmbH, Hilden, Germany) according to the manu-
facturer’s instructions. cDNAs were stored at -20°C until further 
processing. Quantification of gene expression was performed by 
qPCR using the DyNAmo Flash SYBR Green qPCR Kit (Thermo 
Fisher, Waltham, USA) according to the manufacturer’s instruc-
tions and assessed in a Stratagene Mx3000P (Agilent Technolo-
gies, California, USA) using the following program: initial dena-
turation, 7 min at 95°C; amplification, 45 cycles with 5 s at 95°C, 
7 s at 60°C and 9 s at 72°C; melting curve analysis, stepwise tem-
perature increase from 50°C to 95°C every 30 s. Data were nor-
malized to the expression of elongation-factor 1-α (EF1A) using 
the ΔCt-method. We used EF1A because of its stable expression 
in MSCs under conditions of inflammation (involving immune 
cell activation and morphological changes), hypoxia, and in dif-
ferent cell types (peripheral immune cells) under different drug 
treatments (Curtis et al., 2010). We excluded several typical 
house-keeping genes such as glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) or β-actin (ACTB)  as these are well known 
to be regulated under hypoxic conditions and after immune cell 
activation, respectively (Foldager et al., 2009). All primers were 
purchased from TIB Molbiol (Berlin, Germany) and are listed in 
Table 3.       
Cytokine and chemokine quantification
Supernatants of the in vitro FHs were immediately frozen after 
48 h and stored at -80°C. The concentrations (pg/mL) of cyto-
kines and chemokines were determined using a multiplex sus-
pension assay (Bio-Rad Laboratories, München, Germany) ac-
cording to the manufacturer’s description. The following cyto-
kines and chemokines (lower detection limit) were measured: 
IL-1β (7.55 pg/mL), IL-2 (18.99 pg/mL), IL-4 (4.13 pg/mL), IL-5 
(20.29 pg/mL), IL-6 (25.94 pg/mL), IL-7 (16.05 pg/mL), IL-8 
(37.9 pg/mL), IL-10 (37.9 pg/mL), IL-13 (7.21 pg/mL), IL-17 
(24.44 pg/mL), interferon-gamma (IFNγ, 56.32 pg/mL), tumor 
necrosis factor-alpha (TNFα, 59.53 pg/mL), monocyte chemo-
tactic protein-1 (MCP-1, 27.02 pg/mL), macrophage inflamma-
tory protein MIP-1β (6.27 pg/mL), granulocyte colony-stimulat-
ing factor (G-CSF, 50.98 pg/mL), granulocyte-macrophage colo-
ny-stimulating factor (GM-CSF, 11.82 pg/mL) and macrophage 
migration inhibitory factor (MIF, 57.78 pg/mL). 
constantly monitored using incubators equipped with CO2-sen-
sors and O2-sensors (Binder, Tuttlingen, Germany).
Donor information for the material used in this study is giv-
en in Table1. For the flow cytometry analysis, the gene expres-
sion analysis and the Bioplex assays in the initial experiments, 
the blood of blood donors B1-B3 was mixed with either MSC1 or 
MSC2 (n = 6). For the treatment studies with either DEX or DFO, 
blood donors B4-B6 were mixed with MSC3 or MSC4 (n = 6). 
Preparation of in vitro FH models for flow cytometry and  
gene expression analysis
Immediately after coagulation (0 h = control) or after cultivation 
for 6, 12, 24 or 48 h in OM, the in vitro FH models were washed 
twice in PBS. Cells were separated using a cell strainer (70 µm, 
Corning, New York, USA). Erythrocyte lysis was conduct-
ed twice at 4°C for 6 min by osmotic shock using erythrocyte 
lysis buffer (0.01 M KHCO3, 0.155 M NH4Cl, 0.1 mM EDTA, 
pH 7.5). Cells were washed in 0.5% BSA in PBS (PBS/BSA).
Flow cytometry analysis
After blocking the unspecific binding of Fc-receptors using a 
solution containing 5 mg/mL human IgG (IgG1 66.6%, IgG2 
28.5%, IgG3 2.7%, IgG4 2.2%; Flebogamma, Grifols, Frankfurt, 
Germany), cells were washed in PBS/BSA and antibody staining 
was performed for 15 min on ice using antibodies and dilutions as 
listed in Table 2. Cells were then washed (PBS/BSA) and centri-
fuged at 300 g for 3 min in a U-bottom 96-well-plate, supernatants 
were discarded, and the pellets were resuspended in 0.05% NaN3 
in PBS/BSA (PBS/BSA/Azide). Shortly before analysis, the cells 
were incubated with 1:25 diluted 7-AAD (BioLegend®, San 
Diego, USA) for 2 min at RT. Cells were assessed using a MACS 
Quant Analyzer (Miltenyi Biotech, Bergisch Gladbach, Germa-
ny) and evaluated using FlowJo software (Tree Star, USA). The 
gating strategy is depicted in Fig. S31.
Gene expression analysis
Total RNA was extracted using the Arcturus™ PicoPure™ RNA 
Isolation Kit (Applied Biosystems, Foster City, USA) according 
to the manufacturer’s instructions. cDNAs were synthesized by re-
verse transcription using the Sensiscript® Reverse Transcription 
Tab. 2: Antibodies used for the characterization of immune cells and MSCs
Antibody Marker for Manufacturer Catalog Number Species of origin Dilution
Monoclonal anti-human CD3 T cells Miltenyi Biotech 130-113-139 REAfinity™ 1:100
Monoclonal anti-human CD4 T helper cells Miltenyi Biotech 130-113-223 REAfinity™ 1:100
Monoclonal anti-human CD8 Cytotoxic T cells Miltenyi Biotech 130-110-684 REAfinity™ 1:100
Monoclonal anti-human CD14 Monocytes Miltenyi Biotech 130-110-521 REAfinity™ 1:100
Monoclonal anti-human CD19 B cells Miltenyi Biotech 130-113-649 REAfinity™ 1:100
Monoclonal anti-human CD45 Pan-Leukocytes Miltenyi Biotech 130-110-633 REAfinity™ 1:50
Monoclonal anti-human CD73 MSCs BioLegend® 3444004 Mouse 1:20
Monoclonal anti-human CD90 MSCs BioLegend® 328114 Mouse 1:20
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sured in the incubator at 5% CO2 and high humidity flushed with 
room air) (Fig. 1). 
Using flow cytometry, we observed a more severe but not sig-
nificant continuous decline in the frequency of living cells after 
an incubation period of 48 h under hypoxia (45 ±4%) as com-
pared to normoxia (55 ±3%; Fig. 1A). More in detail, the frequen-
cy of innate and adaptive immune cells decreased constantly un-
der hypoxic and normoxic conditions (Fig. 1B). Interestingly, the 
frequencies of cells representing the adaptive immune response, 
namely T helper cells (CD45+/CD3+/CD4+), cytotoxic T cells 
(CD45+/CD3+/CD8+), and B cells (CD45+/CD19+) significant-
ly decreased at 48 h under hypoxic as compared to normoxic in-
cubation. In contrast, cells of the innate immune response, such 
as granulocytes (CD45+/SSChigh), which were the most abun-
dant cell population until 24 h (25 ±4%), and monocytes (CD45+/ 
SSCintermediate/CD14high), did not differ in their frequencies 
with regard to oxygen availability.
The frequency of MSCs (CD45-/CD90+/CD73+) within the 
in vitro FH models constantly increased over time, becoming 
the most abundant cell population with approximately 20% after 
48 h of incubation. Interestingly, this effect was even more pro-
nounced under hypoxic conditions, particularly after 48 h, where 
the frequency of MSCs within the in vitro FH models was sig-
nificantly higher under hypoxic compared to normoxic conditions 
(23 ±4% vs. 13 ±4%). Thus, hypoxic incubation reduced the fre-
quency of cells of the adaptive immune response and increased 
the frequency of MSCs, the precursors of chondrocytes and os-
teoblast/osteocytes important for bone healing.     
3.2  Gene expression profile reveals the 
upregulation of markers relevant for fracture 
healing in the in vitro FH models
With the intention to analyze the impact of hypoxia – most prom-
inent at 48 h – on a selected gene expression pattern, we investi-
gated the expression of marker genes for osteogenesis (RUNX2, 
SPP1), angiogenesis (VEGFA, IL8, MMP2, MMP9), inflamma-
For the dexamethasone and DFO treatment experiments, we 
set the values of cytokines/chemokines that were not detectable 
in the samples to the values of the corresponding detection limit.
Statistical analysis 
Statistical analysis was conducted using GraphPad Prism (Ver-
sion 7, La Jolla, USA). The gene expression and Bioplex data are 
given as mean ± SEM. Flow cytometry data are given as median 
± range. All data sets were tested for normal distribution. Since 
the data sets were not normally distributed, non-parametric tests 
were performed. Differences between the time points were com-
pared using the Mann Whitney U test. Differences between nor-
moxia and hypoxia or hypoxia vs. dexamethasone/DFO treatment 
were compared using the Wilcoxon signed rank test (*p < 0.05, 
**p < 0.01, ***p < 0.005, ****p < 0.0001).
3  Results
3.1  Temporal cellular composition of the in vitro FH 
models is dominated by long-term survival of MSCs
In order to simulate the first phase of fracture healing in vitro, 
we generated in vitro FH models consisting of human MSCs and 
peripheral blood cells. Here and in the following experiments, 
we only used cells meeting the minimal criteria for MSCs set by 
the Mesenchymal and Tissue Stem Cell Committee of the Inter-
national Society for Cellular Therapy (Dominici et al., 2006), 
shown in Figure S1 and S21, which guarantees the consistent 
quality of the MSCs in the various tests performed. 
In consideration of mimicking the fracture gap microenviron-
ment characterized by hypoxia and to evaluate its impact on tem-
poral distribution and cell composition, we incubated the in vitro 
FH models for 6, 12, 24 and 48 h under hypoxic conditions (1% 
O2, which is the average oxygen level measured in the incubator 
at 5% CO2 and high humidity flushed with nitrogen) as compared 
to normoxia (18% O2, which is the average oxygen level mea-
Tab. 3: Primers used
Gene symbol Gene name Forward primer  Reverse primer 
SPP1 Secreted phosphoprotein 1 GCCGAGGTGATAGTGTGGTT TGAGGTGATGTCCTCGTCGTCTG
VEGFA Vascular endothelial growth factor A AGCCTTGCCTTGCTGCTCTA GTGCTGGCCTTGGTGAGG
RUNX2 Runt-related transcription factor 2 TTACTTACACCCCGCCAGTC TATGGAGTGCTGCTGGTCTG
EF1A Elongation factor 1-alpha GTTGATATGGTTCCTGGCAAGC TTGCCAGCTCCAGCAGCCT
MMP2 Matrix metalloproteinase-2 GATACCCCTTTGACGGTAAGGA CCTTCTCCCAAGGTCCATAGC
IL8 Interleukin 8 GGACCCCAAGGAAAACTGG CAACCCTACAACAGACCCACAC
IL6 Interleukin 6 TACCCCCAGGAGAAGATTCC TTTTCTGCCAGTGCCTCTTT
PGK1 Phosphoglycerate kinase 1 ATGGATGAGGTGGTGAAAGC CAGTGCTCACATGGCTGACT
LDHA Lactate dehydrogenase A ACCCAGTTTCCACCATGATT CCCAAAATGCAAGGAACACT
MMP9 Matrix metalloproteinase-9 CCTGGAGACCTGAGAACCAATC CCACCCGAGTGTAACCATAGC
HIF1A Hypoxia-inducible factor 1-alpha CCATTAGAAAGCAGTTCCGC TGGGTAGGAGATGGAGATGC
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tion under normoxic conditions when compared to 0 h (Fig. 2B). 
In contrast, IL6 gene expression, which is well-known to be in-
duced under inflammatory conditions, was significantly lowered 
after 48 h incubation under normoxic (pIL6 = 0.0138) conditions 
but remained unaltered after 48 h incubation under hypoxic con-
ditions, resulting in a significantly higher expression under hy-
poxic compared to normoxic conditions after 48 h of incubation 
(pIL6 = 0.03; Fig. 2B).
The CXCR4 transcript encodes the information of the re- 
ceptor for stromal cell derived factor 1 (SDF-1), which is well-
known to facilitate migration of a variety of cell types, includ-
ing the recruitment of MSCs, towards the fracture site. The ex-
pression of CXCR4 was significantly induced after 48 h com- 
pared to 0 h irrespective of oxygen availability (pnormoxia = 0.005; 
phypoxia = 0.002; Fig. 2C). Moreover, gene expression of MMP2 
and MMP9, encoding for matrix metalloproteinases and important 
for vascularization and migration, were significantly up-regulat-
ed after 48 h as compared to 0 h under hypoxic but not under nor-
moxic conditions (pMMP2 = 0.0197, pMMP9 = 0.002; Fig. 2C). Both 
genes were significantly more highly expressed when comparing 
normoxia vs hypoxia (pMMP2 = 0.0244, pMMP9 = 0.0137).
Typical markers for cellular adaptation towards hypoxia (LDHA, 
 PGK1, and HIF1A) were significantly more highly expressed af-
ter 48 h of incubation under hypoxic when compared to normox-
ic conditions (pLDHA = 0.008, pPGK1 = 0.031, pHIF1A = 0.027; Fig. 
2D). While LDHA was also significantly up-regulated after 48 h 
of incubation under hypoxia but not normoxia compared to 0 h 
(p = 0.0002), PGK1 demonstrated a trend towards an increased 
tion (SPP1, IL6, IL8), migration (CXCR4, MMP2, MMP9), and 
hypoxic adaptation (HIF1A, LDHA, PGK1) of in vitro FH mod-
els incubated in OM under hypoxic or normoxic conditions for 
48 h (Fig. 2). Although, we also investigated the gene expression 
for the time points 0, 6, 12 and 24 h (Fig. S41), we here focus on 
the effects after 48 h of incubation. Almost all levels of analyzed 
marker genes demonstrated a significant hypoxia-mediated induc-
tion at 48 h as compared to 0 h except for IL6, HIF1A, and PGK1. 
Moreover, compared to normoxic incubation, only CXCR4
 and IL8 were not significantly induced under hypoxic incubation 
at this time point. 
More in detail, the osteogenic markers, namely the transcrip-
tion factor RUNX2 as well as SPP1, were significantly up-regu-
lated after 48 h of incubation under hypoxic conditions as com-
pared to 0 h (pRUNX2 = 0.006, pSPP1 < 0.0001) (Fig. 2A). Only 
SPP1, but not RUNX2, was significantly induced after 48 h incu-
bation under normoxic conditions (pSPP1 < 0.0001). Both osteo-
genic marker genes demonstrated a significant increase in gene 
expression under reduced oxygen availability (pRUNX2 = 0.023, 
pSPP1 = 0.009). 
The angiogenic marker VEGFA was significantly up-regulated 
after 48 h incubation under hypoxia (pVEGFA = 0.0003) but not un-
der normoxia as compared to 0 h (Fig. 2B). Furthermore, VEGFA 
was significantly up-regulated after 48 h as compared to incuba-
tion under normoxic conditions (pVEGFA = 0.0049). The pro-in-
flammatory and pro-angiogenic IL8 was significantly up-regulat-
ed under hypoxia when compared to normoxia (pIL8 = 0.0017), 
with no significant alterations in expression after 48 h incuba-
Fig. 1: Hypoxia favors 
survival of MSCs while 
T- and B-cell fractions are 
significantly decreased
(A) Frequency of total cells 
negative for 7-AAD in the 
FH cultured in osteogenic 
differentiation medium under 
normoxic (NOX; 18% O2) or 
hypoxic conditions (HOX;  
1% O2) for 6, 12, 24 and 48 h 
(median ± range, n = 6).  
(B) Frequency of immune cell 
populations (granulocytes, 
CD14+ monocytes, CD4+ 
T cells, CD8+ T cells, 
CD19+ B cells) and MSCs 
(CD73+, CD90+, CD45-, 
CD14-) negative for 7-AAD 
in the in vitro FHs cultured 
in osteogenic differentiation 
medium under normoxic or 
hypoxic conditions for 6, 12, 
24 and 48 h (median ± range, 
n = 6). Statistical analysis was 
conducted using the Wilcoxon 
signed ranked test (*p < 0.05).
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MIF and the pro-inflammatory and pro-angiogenic IL-8 as well 
as the chemoattractant protein MCP-1 and the pro-inflammato-
ry G-CSF and GM-CSF were detected (Fig. 3). IL-6 and IL-8 
were detectable in the medium after 48 h incubation under both 
normoxia and hypoxia, with a trend to a higher level in the lat-
ter (pIL-6 = 0.094, pIL-8 = 0.063), while MIF, MCP-1, G-CSF and 
GM-CSF levels were comparable irrespective of oxygen avail-
ability.     
3.4  Dexamethasone favors the survival of immune 
cells over MSCs, suppresses osteogenesis and 
enhances the secretion of inflammatory cytokines
To determine whether the in vitro FH model is suitable to reflect 
the known glucocorticoid-mediated disturbance of the initial 
healing phase, we analyzed the impact of the glucocorticoid dexa-
expression (p = 0.086) and HIF1A showed a decrease for both 
normoxia and hypoxia.
Taken together, almost all markers of gene expression that are 
important for proper fracture healing demonstrated a significant 
hypoxia-mediated induction after 48 h.   
3.3  Hypoxia does not significantly impact cytokine/ 
chemokine levels in the supernatant of in vitro FH models
In order to confirm the gene expression pattern of pro-angiogenic 
and pro-inflammatory markers after 48 h incubation and to char-
acterize the secretion of cytokines and chemokines, we analyzed 
the respective supernatants. While IL-1β, IL-2, IL-4, IL-5, IL-
7, IL-10, IL-13, IL-17, TNFα and IFNγ were not detectable in 
the supernatants of the in vitro FH models, certain levels of the 
pro-inflammatory IL-6, pro-inflammatory and pro-angiogenic 
Fig. 2: Osteogenic, angiogenic, 
inflammatory, migration and metabolic 
markers are significantly upregulated 
after 48 h of incubation, more 
pronounced under hypoxia, in FHs
Relative gene expression within the in vitro 
FHs after cultivation in OM for 48 h of (A) 
the osteogenic markers RUNX2 and SPP1, 
(B) the angiogenic/inflammatory markers 
VEGFA, IL8, IL6, (C) the migration markers 
CXCR4, MMP2 and MMP9, and (D) the 
metabolic markers HIF1A, LDHA and PGK1. 
The expression is shown at 0 h (white bars) 
and under normoxia (NOX; light grey bars) 
or hypoxia (HOX; dark grey bars). All values 
are normalized to the “housekeeping gene” 
EF1A (mean ± SEM, n = 12). Statistical 
analysis was conducted using the Mann 
Whitney U test to compare the values to 
0 h, and the Wilcoxon signed rank test to 
compare normoxia and hypoxia (*p < 0.05, 
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3.5  Chemical induction of hypoxia using DFO does  
not fully mimic hypoxic  
conditions created in a hypoxia-incubator
DFO has been widely reported to increase fracture-healing prop-
erties by supporting HIF-mediated angiogenesis and osteogene-
sis independent of species, model and evaluation methods (Don-
neys et al., 2013a,b, 2015, 2016; Drager et al., 2016, 2017; Far-
berg et al., 2012; Guzey et al., 2016; Matsumoto and Sato, 2015; 
Shen et al., 2009; Stewart et al., 2011; Yao et al., 2016; Zhang et 
al., 2012; Kang et al., 2016; Kusumbe et al., 2014; Li et al., 2015; 
Liu et al., 2014; Wang et al., 2017b). To simulate the clinical ap-
plication of DFO to overcome an inadequate hypoxic response in 
patients that are prone to delayed healing, we treated the in vitro 
FH models with 250 µM DFO under normoxic conditions (Fig. 
5) or left them untreated (for comparison, treatment under hy-
poxic conditions is shown in Fig. S51). 
Focusing on the frequencies of total live cells (Fig. 5A), we did 
not observe any difference after treatment with DFO as compared 
to the normoxic untreated control in vitro FH models. Interest-
ingly, the frequency of the individual cell populations displayed 
a significantly reduced frequency of T cells after DFO treatment. 
Both the frequency of T helper cells as well as the frequency of 
cytotoxic T cells significantly declined upon DFO treatment in 
the in vitro FH models (10 ±3% to 7 ±2% and 5,5 ±1% to 4 ±1%; 
p = 0.03). Conversely, the proportion of granulocytes was sig-
nificantly higher in the DFO-treated group (28 ±3%) compared 
to the normoxic control group (18 ±2%; p = 0.03). No other cell 
population analyzed demonstrated considerable differences be-
tween both conditions.
methasone (DEX) at a clinically relevant dose of 10-7 M under 
physiological conditions (under hypoxia and in a pro-osteogenic 
environment) after 48 h of incubation as compared to the untreat-
ed control. Surprisingly, DEX treatment diminished the frequency 
of living cells within the in vitro FH models to a lesser extent than 
the corresponding control (Fig. 4A). Upon closer analysis, DEX 
significantly reduced the frequency of MSCs while increasing the 
proportions of all immune cell populations analyzed, leading to 
an enrichment of the granulocyte population (25 ±4%) within the 
DEX-treated in vitro FH models. In line, gene expression analy-
sis demonstrated that the expression of osteogenic marker genes 
(RUNX2, SPP1) was significantly diminished in the FH models 
after treatment with DEX as compared to the untreated control 
(Fig. 4B). Similarly, the gene expression of pro-inflammatory 
IL6 and CXCR4 was significantly reduced in the DEX-treated FH 
models. However, DEX treatment influenced neither the expres-
sion of pro-angiogenic genes (VEGFA, IL8) nor genes involved 
in the adaptation towards hypoxia (PGK1, LDHA, and HIF1A). 
Of note, under normoxic cultivation conditions, DEX abolished 
osteogenic differentiation while inducing lipid droplet formation 
only at a high concentration of 10-5 M DEX but not at the clinical-
ly relevant dose of 10-7 M (Fig. S71). 
Focusing on the release of cytokines and chemokines after 
DEX treatment under hypoxic conditions, we detected IL-4, IL-
6, IL-8, IL-17, IFNγ, TNFα, G-CSF, GM-CSF, MIF and MCP-1 
in considerable amounts in the supernatant of in vitro FH models 
(Fig. 4C). Interestingly, all factors detected demonstrate a higher 
abundance in the supernatant of in vitro FH models treated with 
DEX but remained low in the untreated controls.  
Fig. 3: Induction of angiogenic as 
well as pro-inflammatory cytokines/
chemokines in FHs
In vitro FHs were incubated under normoxia 
(NOX) or hypoxia (HOX) for 48 h in 
osteogenic medium, and the concentration 
of cytokines and chemokines was 
measured in the supernatant.  
Values represent median ± range  
(n = 6) of secreted protein (pg/mL) in 
the supernatant. Statistical analysis via 
Wilcoxon signed rank test. p values indicate 
statistical trends (p < 0.1).
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Fig. 4: Dexamethasone favors 
the survival of immune cells over 
MSCs, suppresses osteogenesis, 
and enhances the secretion of 
inflammatory cytokines 
In vitro FHs were incubated under 
hypoxia (HOX) in the presence or 
absence of 10-7 M dexamethasone 
(Dex) for 48 h in OM. (A) Frequency 
of total cells and individual cell 
populations negative for 7-AAD,  
(B) relative gene expression of 
relevant genes normalized to EF1A, 
and (C) concentration of secreted 
protein (pg/mL) in the supernatant 
(C). Values represent the median  
± range (n = 6) for the cell 
composition analysis and the mean  
± SEM (n = 6) for the gene 
expression and the secreted 
proteins. Statistical analysis was 
conducted using the Wilcoxon signed 
rank test (*p < 0.05).
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4  Discussion
In order to provide a pre-clinical model of the initial healing 
phase, we established an in vitro FH model based on human cells 
that can be used (i) to investigate cellular mechanisms and adap-
tive processes during the initial phase of fracture healing, (ii) to 
identify new potential therapeutic targets, and (iii) to determine 
the efficacy and effectiveness of therapeutics for the treatment of 
fracture healing disorders (iv) to effectively reduce the number 
of animal experiments. 
Regarding the gene expression pattern (Fig. 5B), we observed 
a greater expression of the early osteogenic transcription factor 
RUNX2 (p = 0.06) and the inflammatory markers IL6 (0.1) and 
IL8 (p = 0.06) after treatment with DFO compared to the control 
group. Additionally, genes involved in the adaptation to hypoxic 
conditions were more highly expressed in the group treated with 
DFO compared to the corresponding normoxic controls (pPGK1 = 
0.04, pHIF1A = 0.03). Generally, the treatment with DFO did not 
lead to a significantly higher cytokine/chemokine release com-
pared to normoxia (Fig. 5C).    
Fig. 5: DFO significantly increases 
the frequency of granulocytes, 
decreases the frequency of T cells, 
and enhances the expression of 
hypoxia-related and inflammatory 
markers
In vitro FH models were incubated 
under normoxia (NOX) in the presence 
or absence of 250 µM DFO for 48 h 
in osteogenic medium. (A) Frequency 
of total cells and individual cell 
populations negative for 7-AAD,  
(B) relative gene expression of relevant 
genes normalized to EF1A, and  
(C) concentration of secreted protein 
(pg/mL) in the supernatant (C). Values 
represent the median ± range (n = 6) 
for the cell composition analysis and 
the mean ± SEM (n = 6) for the gene 
expression and the secreted proteins. 
Statistical analysis was conducted 
using the Wilcoxon signed rank test  
(*p < 0.05).
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In our FH model, we observed an increase in the frequency 
of MSCs, key players in the initial phase of fracture healing, 
which generate the precursors of chondrocytes and osteoblast/
osteocytes, which are essential for proper bone healing (Knight 
and Hankenson, 2013; Kolar et al., 2011; Hoff et al., 2016), and 
are capable of terminating the inflammatory phase (Kolar et al., 
2011) by inhibition of immune cell proliferation (Le Blanc et al., 
2003; Madrigal et al., 2014; Gieseke et al., 2007; Bocelli-Tyndall 
et al., 2007; Potian et al., 2003; Kovach et al., 2015), thereby 
modulating the immune response and conveying immune toler-
ance (Nauta and Fibbe, 2007). The shift of the cellular distribu-
tion to a pattern dominated by MSCs also influences the gene 
expression pattern in our FH model, demonstrating a significant 
hypoxia-mediated induction after 48 h, especially for hypoxia re-
sponse and osteogenic marker gene expression (Fig. 2), while not 
significantly altering but enhancing inflammatory cytokine and 
chemokine levels in the supernatant (Fig. 3). The induction of a 
hypoxia response and osteogenic marker gene expression as well 
as no further induction of inflammatory cytokine and chemok-
ine levels have been proposed to be important for proper fracture 
healing (Hoff et al., 2011). 
Focusing on the gene expression pattern under hypoxic incuba-
tion conditions, we could successfully mimic the situation in the 
fracture gap by confirming the findings observed in hematomas 
derived from 40 patients obtained between 48 and 72 h after sur-
gery (Kolar et al., 2011) as summarized in Table 4. Additionally, 
in this study we confirmed that hypoxia promotes osteogenesis of 
MSCs as reported previously (Haque et al., 2013; Wagegg et al., 
2012; Lennon et al., 2001). Moreover, we observed secretion of 
pro-angiogenic (IL-8) and pro-inflammatory cytokines/chemok-
ines (IL-6, G-CSF, GM-CSF, and MCP), factors well-known to 
be responsible for the recruitment and activation of leukocytes in 
an inflammatory milieu, after incubation for 48 h under both nor-
moxia and hypoxia (Fig. 3), confirming the findings of our previ-
ous study using hematomas derived from 40 patients (Hoff et al., 
2016). Unexpectedly, we could not observe a relevant amount 
of the early inflammatory markers TNFα and IL-1β. However, 
Granero-Molto et al. (2009) also reported decreased secretion of 
TNFα and IL-1β after transplanting MSCs into the fracture gap 
using a stabilized tibia fracture mouse model.
Although our FH model has some limitations with regard to 
the completeness of cell types involved, we could demonstrate a 
decrease in the frequency of lymphocytes and an increase in the 
frequency of MSCs after 48 h of incubation under hypoxic con-
ditions, suggesting the capacity of MSCs to restrict the initial in-
flammatory phase of fracture healing while initiating osteochon-
dral differentiation. 
For technical reasons, we combined peripheral blood and 
MSCs from different donors (allogenic combination), as the 
MSCs were cultured for some weeks before being combined 
with fresh blood. We considered this unproblematic as MSCs 
have been characterized as immune-privileged, immune evasive 
(Ankrum et al., 2014) and/or, in some conditions, immunosup-
pressive (e.g., in case of T cell proliferation). However, the acti-
vation of immune cells via allogenic MSCs is still controversial-
ly discussed as previously reviewed in detail (Hare et al., 2012; 
Rozier et al., 2018; Zhang et al., 2015). Here, we observed that 
Mimicking the in vivo situation of the fracture gap by apply-
ing a hypoxic microenvironment, we observed a predominant 
reduction in the frequency of adaptive immune cells and an 
increase in the frequency of MSCs (Fig. 1). Of note, the trau-
ma-induced rupture of blood vessels opens the bone channel 
and forms a hematoma of clotted bone marrow/blood, consist-
ing mostly of immune cells, their precursors, and endothelial 
and stromal cells, which initiates the cascade of bone regenera-
tion by further recruitment of immune cells and MSCs (Knight 
and Hankenson, 2013). 
While the importance of MSCs as precursors of chondrocytes 
and bone cells (osteoblasts and osteocytes) (Knight and Hanken-
son, 2013; Kolar et al., 2011; Hoff et al., 2016) and as termina-
tors of the inflammatory phase, resembling the in vivo situation 
(Kolar et al., 2011), is undisputed, the role of immune cells such 
as granulocytes, T and B cells remains controversial (Kovtun et 
al., 2016; Grogaard et al., 1990; El Khassawna et al., 2017; Kon-
necke et al., 2014; Reinke et al., 2013; Toben et al., 2011). Al-
though generally, cells rich in mitochondria often have an intrin-
sic need for sufficient oxygen supply and are barely able to cope 
with hypoxic conditions (e.g., neuronal cells), the survival capac-
ity and activation status of immune cells (T cells, B cells, mono-
cytes, neutrophils) is enhanced under hypoxic conditions, main-
ly due to activation/stabilization of the HIF-signaling pathway in 
an oxygen-restricted environment (Krzywinska and Stockmann, 
2018). In terms of MSCs, hypoxia seems to favor MSC survival 
and their differentiation towards the chondrogenic and osteogen-
ic lineages once differentiation is induced, while adipogenesis is 
reduced (Wagegg et al., 2012; Lee et al., 2016). However, wheth-
er inflammatory cells and MSCs actually differ in their tolerance 
of oxygen is still a matter of research. 
Using RAG1-deficient mice, which lack an adaptive immune 
system, Toben et al. (2011) demonstrated enhanced fracture heal-
ing due to accelerated endochondral ossification and a shift from 
pro-inflammatory to anti-inflammatory cytokines (Toben et al., 
2011). Moreover, depletion of only CD8+ T cells also enhanced/
accelerated fracture healing in a mouse osteotomy model, indi-
cating a possible contribution of adaptive immune cells to de-
layed or disturbed fracture healing (Reinke et al., 2013; Toben 
et al., 2011). Nevertheless, T and B cells evidently contribute to 
a higher bone quality in the later stages of fracture healing by fa-
cilitating the collagen organization process (El Khassawna et al., 
2017; Konnecke et al., 2014). However, granulocytes, which are 
responsible for the removal of dead cells and cell debris in the 
very initial phase after trauma (Soehnlein et al., 2009), and which 
are the most abundant cell fraction in the early FH (Kovtun et 
al., 2016), provide an “emergency extracellular matrix” for in-
filtrating stromal cells (Bastian et al., 2016), thereby essential-
ly contributing to proper fracture healing (Kovtun et al., 2016). 
Although Groogard et al. (1990) did not observe any impact of 
neutropenia on callus formation in rats, Kovtun et al. (2016) ob-
served diminished bone content, impaired mechanical properties 
and bone healing after 21 days in fractured mice after using an 
anti-Ly-6G-antibody to reduce neutrophil numbers. Using pa-
tient-derived isolated ex vivo FHs, we previously reported a de-
crease of granulocytes already after 24 h of incubation, which 
was even more pronounced under hypoxia (Hoff et al., 2013).
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demonstrated that glucocorticoids delayed fracture healing and 
impaired bone biomechanical properties in mice. Taken together, 
the effects of DEX within our model may resemble the processes 
of delayed or impaired fracture healing. 
In contrast to DEX, DFO has been reported to support angio-
genesis (Farberg et al., 2014), to enhance the vascular response to 
fractures (Donneys et al., 2012), and to augment the restoration 
and mineralization of the callus (Donneys et al., 2013a), mak-
ing it an attractive off-label therapeutic target with regard to frac-
ture healing. Additionally, DFO stabilizes HIF-1α by suppressing 
the oxygen-sensitive prolyl hydroxylases (PHDs), which are re-
sponsible for the tagging of HIF-1α for proteasomal degradation, 
thereby mimicking hypoxic conditions and markedly improving 
osteogenesis (Qu et al., 2008) and bone regeneration (Wan et al., 
2008). To simulate the clinical application of DFO to overcome 
an inadequate hypoxic response in patients that are prone to de-
layed healing as demonstrated previously (Kolar et al., 2011), we 
treated the in vitro FH models with 250 µM DFO under normox-
ic conditions (Fig. 5) or left them untreated (treatment under hy-
poxic conditions are shown in Fig. S51). Here, we used DFO as 
a hypoxia mimicking agent to overcome a delay or failure of the 
cells to adapt to hypoxic conditions, which we simulated using 
normoxic incubation conditions. As a result, we observed that the 
frequency of T helper cells as well as of cytotoxic T cells (Fig. 5) 
was diminished when treated with DFO compared to normox-
ia, while the frequency of granulocytes was significantly high-
er. This finding can be explained by an anti-proliferative effect 
of DFO on activated T lymphocytes, but with barely any effect 
on granulocytes as demonstrated by Hileti et al. (1995). Similar-
ly, DFO has been demonstrated to diminish proliferation and sur-
vival of MSCs (Zeng et al., 2011; Wang et al., 2017a), which may 
explain the decline in the frequency of MSCs as compared to 
normoxia in our model. However, as expected, DFO-treatment as 
well as hypoxia up-regulated HIF1A, PGK1 and LDHA as com-
pared to their corresponding controls while only RUNX2, which 
is a very early marker for osteogenic processes, but not SPP1, the 
downstream marker of osteogenesis, was induced by DFO-treat-
ment. With regard to the secretion of cytokines, IL-6 and IL-8 
were both similarly secreted, whereas DFO-treatment resulted 
in scarcely any enhanced secretion of G-CSF, GM-CSF, MCP-
1 and MIP-1β compared to normoxia and therefore did not con-
tribute to an enhancement of inflammation as observed for DEX 
treatment. Although the treatment with DFO could not fully rec-
reate the situation obtained by incubation under hypoxic condi-
tions, DFO enhanced the expression of hypoxia adaptation-rele-
vant genes and pro-osteogenic factors (RUNX2), thus promoting 
cellular adaptation to hypoxic conditions and the pro-osteogenic 
phenotype of MSCs found in the fracture gap. 
Although we were able to mimic key features of the initial 
phase of fracture healing in vitro, the model still has room for im-
provement. The in vitro FH model presented here is under devel-
opment and still requires optimization and qualification. To opti-
mize the model, we will have to overcome technical challenges 
that forced us to use an allogenic approach; the optimal model 
should be derived from autologous and xeno-free material (au-
tologous serum, MSCs and peripheral blood). Furthermore, we 
T cells in combination with allogenic MSCs remained quies-
cent with regard to the expression of the early activation mark-
er CD69 and the late activation marker CD25 (Fig S61). The ob-
served restriction of inflammation may underline the well-known 
therapeutic benefit of allogenic MSC transplants, which have no 
obvious disadvantages compared to autologous MSC transplan-
tation (Rozier et al., 2018). 
Finally, we compared the established in vitro FH model to ex 
vivo data from primary human FHs obtained between 48 and 72 h 
after trauma and found profound similarities with regard to da-
ta from flow cytometry, gene expression and cytokine secretion 
(Tab. 4 and 5). Interestingly, we also found similar trends with re-
gard to the cell composition, gene expression pattern and the ef-
fects of hypoxia after 48 h of incubation in an equine in vitro FH 
model (Pfeiffenberger et al., 2019). 
In order to further validate the applicability of the in vitro FH 
model for drug testing, we treated the in vitro FHs with either 
DEX (impairs fracture healing) or DFO (supports fracture heal-
ing), in order to mimic either impaired or supported bone heal-
ing processes during the initial phase of fracture healing (Fig. 4 
and 5). 
DEX belongs to the wide class of glucocorticoids that signifi-
cantly improve the quality of life of many patients suffering from 
diseases caused by a dysregulated immune system based on their 
strong immunosuppressive, anti-inflammatory and anti-allergic 
effects on immune cells, tissues and organs (Strehl et al., 2019). 
However, glucocorticoids are also known to influence bone me-
tabolism by inhibiting bone formation, enhancing bone resorp-
tion and impairing adequate bone healing (Canalis, 2003; Fren-
kel et al., 2015; Sato et al., 1986; Sawin et al., 2001; Waters et al., 
2000). Here, we incubated the in vitro FH models with a thera-
peutic dose of 10-7 M DEX for 48 h under pathophysiologic hy-
poxia. Upon treatment with DEX, we observed a significantly 
lower frequency of MSCs and significantly higher frequencies of 
immune cells, suppressed osteogenic gene expression (RUNX2, 
SPP1), and enhanced secretion of inflammatory cytokines (Fig. 
4). Although DEX is well-known to induce apoptosis, particular-
ly in T cells, and suppresses T cell activation (Xing et al., 2015), 
during co-incubation of MSCs and immune cells (e.g., PBMCs), 
DEX has been reported to enhance immune cell proliferation 
and reverse the immunosuppressive effect of MSCs (Chen et al., 
2014; Buron et al., 2009). Regarding the latter finding, DEX has 
been shown to even reverse the anti-inflammatory effect of trans-
planted MSCs as shown by Chen et al. (2014) in a mouse model 
of liver cirrhosis. Furthermore, in vitro osteoblastic differentia-
tion is delayed by treatment with DEX (Canalis, 1996) as indicat-
ed also in the in vitro FH model by a reduced osteogenic gene ex-
pression (RUNX2, SPP1). We and others have also reported that 
DEX suppresses hypoxia-induced HIF-target gene expression 
(Wu et al., 2014; Gaber et al., 2011), which could be confirmed 
in the in vitro FH model based on reduced gene expression of 
VEGFA, LDHA, and CXCR4. Although, DEX is well-known to 
suppress inflammation (Strehl et al., 2019), we observed an en-
hanced secretion of inflammatory cytokines, which may lead to 
delayed or disturbed bone healing as suggested from ex vivo pa-
tient-derived data (Hoff et al., 2011). Indeed, Liu et al. (2018) 
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Tab. 4: Gene expression data from our in vitro FH model (n = 12, 48 h incubation under hypoxia) and from an ex vivo study  
using primary human fracture hematomas obtained between 48 and 72 h after trauma (n = 40) (Kolar et al., 2011)a
Gene Importance in the fracture healing process In vitro FH  Ex vivo 
symbol  model primary 
  (hypoxia human FHs 
  for 48 h) (< 72 h)
RUNX2 Key regulator that directs mesenchymal stromal cells towards the osteoblastic lineage ↑** ↑ 
 (Vimalraj et al., 2015; Komori, 2010).
SPP1 Coding gene for osteopontin (OPN) is a differentiation marker for osteoblastic cells induced ↑**** ↑* 
 by hypoxia (Denhardt and Noda, 1998; Sila-Asna et al., 2007; Gross et al., 2005).   
VEGFA Most important pro-angiogenic factor (Schipani et al., 2009; Martin et al., 2009;   ↑*** ↑* 
 Beamer et al., 2010) essential for the reestablishment of oxygen supply and promotes  
 osteogenesis (Hoff et al., 2016; Grosso et al., 2017).
IL8 Responsible for the activation and differentiation of leukocytes in an inflammatory  ↑** ↑*** 
 osteogenesis environment (Herman et al., 2008).
IL6 Key cytokine in the initial phase of fracture healing (Cassuto et al., 2018). ↑ ↑***
CXCR4 Responsible for the homing of MSCs, promotes bone repair (Liu et al., 2013;  ↑** ↑* 
 Yellowley, 2013) and reflects the migratory capacity of immune and stem cells 
 (Campbell et al., 2003; Kunkel and Butcher, 2002).
LDHA (Hypoxia-mediated) marker of induced glycolysis, contributes to acidic pH, HIF-target gene ↑*** ↑** 
 (Semenza, 1998; Gaber et al., 2005).
PGK1 (Hypoxia-mediated) marker of induced glycolysis (Semenza, 1998; Gaber et al., 2005). ↓ ↑
HIF1A Master regulator of the adaptation towards a hypoxic microenvironment in a large quantity  ↓ ↑** 
 of different cell types (Semenza, 1998; Gaber et al., 2005) regulated on protein- but not on  
 mRNA-level (Semenza, 1998; Gaber et al., 2005).
MMP2 Remodeling of extracellular matrix, crucial for the survival of bone cells and vasculogenesis/ ↑* n.a. 
 angiogenesis and fracture healing (Stamenkovic, 2003; Paiva and Granjeiro, 2017;  
 Varghese, 2006; Cui et al., 2017; Lieu et al., 2011).
MMP9 Remodeling of extracellular matrix, crucial for the survival of bone cells and vasculogenesis/ ↑** n.a. 
 angiogenesis and fracture healing (Stamenkovic, 2003; Paiva and Granjeiro, 2017;  
 Varghese, 2006; Cui et al., 2017; Colnot et al., 2003).
a up-↑ or down-↓ regulation of the genes. *p < 0.05, **p < 0.01, ***p < 0.001, n.a. = not analyzed
Tab. 5: Cell frequencies from our in vitro FH model (n = 6, 48 h incubation under hypoxia) and from an ex vivo study  
using primary human fracture hematomas obtained between 48 and 72 h after trauma (n = 40) (Kolar et al., 2011)
Cell type CD surface marker In vitro FH model Ex vivo primary human FHs  
  (hypoxia for 48 h) (< 72 h)
T cells CD45+CD3+ 3.7% (2.4-10.6%) 8.2% (1.1-39.4%)
T helper cells CD45+CD3+CD4+ 1.9% (1.1-6%) 3.1% (1.4-15.4%)
Cytotoxic T cells CD45+CD3+CD8+ 1.3% (0.9-2.5%) 1.9% (0.2-12.6%)
Monocytes Scatter and CD45+CD14+ 0.6% (0.3-1.7%) 4.9% (0.1-38.5%)
B cells  CD45+CD3-CD19+ 0.25% (0.2-0.4%) 0.9% (0.1-5.8%)
MSCs CD45-CD73+CD90+ 23.4% (16.6-24.5%) n.a.
Granulocytes Scatter and CD45+ vs. CD16+ 16.1% (5.6-24.7%) 64.2% (0.8-94%)
Not assigned cells n. a. 37.1% (27.6-45.8%) 12.2% (1.2-85.6%)
Frequency of cells (min-max in %). Granulocytes gated in vitro via CD45+/ FSC-SSC-gate, ex vivo via CD16; n.a., not analyzed
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would like to include further cell types present in the bone mar-
row and in the fracture gap, including hematopoietic stem cells 
and cells of their subsequent progenitor lineages, endothelial 
progenitor cells and perivascular cells (Braham et al., 2019). Fi-
nally, we wish to implement the model into a perfusion system to 
provide better nutrient supply and waste removal, which we plan 
to achieve by using a bioreactor platform. This promises to ex-
tend the life-time of our model to allow the study of later phases 
of bone regeneration. 
Prospectively, the established and optimized model will pro-
vide the opportunity to (1) study cellular and humoral processes 
of bone regeneration, (2) investigate the underlying mechanisms 
of how hypoxic conditions modulate cell survival, proliferation, 
communication and differentiation during the initial phase of 
fracture healing, (3) screen for new potential therapeutics and as-
sess their efficacy to support fracture healing and to treat fracture 
healing disorders, and (4) determine side effects of pharmacolog-
ical substances.                      
5  Conclusion
In the study presented here, we developed an in vitro hu-
man-based FH model using human MSCs and human peripheral 
blood as a tool for preclinical drug testing. We characterized key 
mechanisms important for proper fracture healing and demon-
strated that hypoxia preferred the survival of MSCs to immune 
cells. Fracture-healing relevant genes/factors were considerably 
upregulated after 48 h of incubation, most often significantly en-
hanced by hypoxia. Additionally, cytokines/chemokines that are 
crucial during the initial phase of fracture healing were secreted. 
These findings resemble previous results from our group from an 
ex vivo study using patient-derived FHs. We could highlight sig-
nificant similarities to human in vitro, ex vivo and animal-based 
in vivo data. To prove the suitability of our 3D in vitro FH mod-
el for drug testing, we treated the developed system with DEX or 
DFO, thereby confirming the responsiveness to commonly used 
drugs and newly developed therapeutics. We were able to show 
that both fracture-healing disrupting and fracture-healing pro-
moting substances can influence the in vitro FH model in ways 
similar to what has been observed in vivo. Therefore, we con-
clude that our model is able to correctly mimic human fracture 
hematoma and could reduce the number of animal experiments 
in early preclinical studies.
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